The European Medicines Agency review of sacituzumab govitecan for the treatment of triple-negative breast cancer

Sacituzumab govitecan (SG) is an antineoplastic agent which combines a humanized monoclonal antibody binding to trophoblast cell surface antigen-2 (Trop-2)-expressing cancer cells, linked with cytotoxic moiety SN-38 (govitecan) with topoisomerase I inhibitor action. On 22 November 2021, a marketing...

Descripción completa

Detalles Bibliográficos
Autores principales: Michaleas, S., Moreno Oliver, A., Mueller-Berghaus, J., Sarac, S.B., van der Elst, M.E., Müller-Egert, S., Zander, H., Enzmann, H., Pignatti, F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9149193/
https://www.ncbi.nlm.nih.gov/pubmed/35642987
http://dx.doi.org/10.1016/j.esmoop.2022.100497